Personalized Medicine
Google spinout Verily has raised $300m to advance its AI-driven personalized healthcare platforms and become an independent company.
Merck's post-Keytruda oncology strategy rests on three pillars – immune deepening, tissue targeting and tumor-intrinsic mechanisms – anchored by patient selection, AI-accelerated discovery and a KRAS bet that could define its next era.
At BIO’s Investor and Growth Summit, investors acknowledged the tough funding environment for early stage neuroscience, but said there are signs of increasing interest in the space.
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.
A massive new proteomics dataset promises to accelerate target identification, biomarker discovery and precision medicine approaches in Alzheimer's, Parkinson's and other neurodegenerative diseases.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
Israeli-American biotech Immunai is mapping the immune system and using AI to predict immune responses to drugs.
“Proper medicine driven by data” is how C4X Discovery Holdings’ CEO Clive Dix sees the future now that his immuno-inflammation focused company has been able to identify IBD genetic response signatures in patients treated with vedolizumab.
Newly public company ArriVent BioPharma presented Phase Ib results at WCLC for its kinase inhibitor, which could be the first drug available specifically for hard-to-treat PACC mutations.
Boehringer presented Phase Ib results for zongertinib and Bayer presented Phase I/II results for BAY 2927088 in NSCLC with HER2 mutations – a rare cancer with ADC Enhertu as a major competitor – at the WCLC meeting.
Data at WCLC showed why the TROP2-targeting ADC datopotamab deruxtecan is most effective in non-squamous NSCLC in second or later lines as presented in overall survival data at the meeting.